Prognostic value of Foxp3+ regulatory T cells in endometrial cancer: a meta-analysis

Endometrial cancer is the second most common gynecologic cancer globally, and the prognosis of advanced or recurrent endometrial cancer is very poor. Currently, the prognostic value of Forkhead box protein P3 (FoxP3)+ regulatory T cells (Tregs) in endometrial cancer is unclear. This meta-analysis aimed to evaluate prognostic significance of Foxp3+ Tregs in endometrial cancer. The authors searched the literature from databases including PubMed, Cocohrane, and Web of Science, and selected four eligible studies for further analysis. Meta-analysis of the survival data from 869 endometrial cancer patients showed that there were no significant differences in overall survival, disease-free survival, relapse-free survival or disease-specific survival between patients with high levels of Foxp3+ Tregs infiltration, and those with low levels of Foxp3+ Tregs. In summary, this meta-analysis provided systemic evidence that Foxp3+ Tregs infiltration is not significantly associated with the prognosis of patients with endometrial cancer.

[1] Siegel R.L., Miller K.D., Jemal A.: “Cancer statistics, 2015”. CA Cancer J. Clin., 2015, 65, 5.

[2] Erdemoglu E., Yalcin Y., Bozkurt K.K., Erdemoglu E.: “Surgical staging of low-risk Stage IA endometrioid endometrial cancers”. Eur. J. Gynaecol .Oncol., 2017, 38, 80.

[3] Kölbl A.C., Schlenk K., Behrendt N., Andergassen U.: “The importance of hCG in human endometrial adenocarcinoma and breast can-cer”. Int. J. Biol. Markers, 2018, 33, 33.

[4] Roli L., Pecoraro V., Trenti T.: “Can NGAL be employed as prognostic and diagnostic biomarker in human cancers? A systematic review of current evidence”. Int. J. Biol. Markers, 2017, 32, e53.

[5] Liotta L.A., Kohn E.C.: “The microenvironment of the tumour-host interface”. Nature, 2001, 411, 375.

[6] Grivennikov S.I., Greten F.R., Karin M.: “Immunity, inflammation, and cancer”. Cell, 2010, 140, 883.

[7] Li H., Fan X., Houghton J.: “Tumor microenvironment: the role of the tumor stroma in cancer”. J. Cell. Biochem., 2007, 101, 805.

[8] Najafi M., Farhood B., Mortezaee K.: “Contribution of regulatory T cells to cancer: A review”. J. Cell. Physiol., 2019, 234, 7983.

[9] DeLeeuw R.J., Kost S.E., Kakal J.A., Nelson B.H.: “The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature”. Clin. Cancer Res., 2012, 18, 3022.

[10] Ibrahim E.M., Al-Foheidi M.E., Al-Mansour M.M., Kazkaz G.A.: “The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis”. Breast Cancer Res. Treat., 2014, 148, 467.

[11] Yeong J., Thike A.A., Lim J.C., Lee B., Li H., Wong S.C., et al.: “Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer”. Breast Cancer Res. Treat., 2017, 163, 21.

[12] Stang A.: “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses”. Eur. J. Epidemiol., 2010, 25, 603.

[13] Workel H.H., Komdeur F.L., Wouters M.C., Plat A., Klip H.G., Eggink F.A., et al.: “CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in en-dometrial adenocarcinoma”. Eur. J. Cancer, 2016, 60, 1.

[14] Kübler K., Ayub T.H., Weber S.K., Zivanovic O., Abramian A., Keyver-Paik M.D., et al.: “Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma”. Gynecol. Oncol., 2014, 135, 176.

[15] de Jong R.A., Leffers N., Boezen H.M., ten Hoor K.A., van der Zee A. G., Hollema H., Nijman H.W.: “Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer”. Gynecol. Oncol., 2009, 114, 105.